Since the PAM, ER, and CDK pathways are interdependent drivers of HR+/HER2- advanced breast cancer, the simultaneous inhibition of these three pathways is expected to disrupt their cooperation and counteract resistance. The gene discussed is ESR1; the disease is breast cancer.